Connection

Co-Authors

This is a "connection" page, showing publications co-authored by JOE Y CHANG and ARA A VAPORCIYAN.
Connection Strength

0.960
  1. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881.
    View in: PubMed
    Score: 0.228
  2. Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 06 01; 107(2):261-269.
    View in: PubMed
    Score: 0.180
  3. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032.
    View in: PubMed
    Score: 0.151
  4. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun. 2024 Apr 11; 15(1):3152.
    View in: PubMed
    Score: 0.060
  5. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept. Cell Rep Med. 2024 Mar 19; 5(3):101463.
    View in: PubMed
    Score: 0.060
  6. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health. 2023 07; 5(7):e404-e420.
    View in: PubMed
    Score: 0.056
  7. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol. 2023 01; 7:e2200540.
    View in: PubMed
    Score: 0.055
  8. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 05 10; 38(14):1569-1579.
    View in: PubMed
    Score: 0.045
  9. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg. 2012 Oct; 94(4):1126-32; discussion 1132-3.
    View in: PubMed
    Score: 0.027
  10. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20.
    View in: PubMed
    Score: 0.027
  11. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1.
    View in: PubMed
    Score: 0.023
  12. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2007 Oct 01; 69(2):350-7.
    View in: PubMed
    Score: 0.019
  13. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36.
    View in: PubMed
    Score: 0.015
  14. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J. 2003 Nov-Dec; 9(6):476-84.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.